Argus Research
- Home
- CABA
CABA
Cabaletta Bio Inc.
as of 03-18-2026 3:58pm EST
$2.97
$0.14
-4.35%
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 319.6M | IPO Year: | 2019 |
| Target Price: | $14.57 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -1.75 | EPS Growth: | -41.82 |
| 52 Week Low/High: | $0.99 - $3.78 | Next Earning Date: | 03-16-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.69 | Index: | N/A |
| Free Cash Flow: | -90433000.0 | FCF Growth: | N/A |
AI-Powered CABA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 72.56%
72.56%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cabaletta Bio Inc. (CABA)
Binder Gwendolyn
Buy
President, Science & Tech.
CABA Jan 21, 2026
Avg Cost/Share
$2.19
Shares
11,312
Total Value
$24,763.10
Owned After
31,312
SEC Form 4
Gerard Michael
Buy
General Counsel
CABA Jan 21, 2026
Avg Cost/Share
$2.27
Shares
6,600
Total Value
$14,979.36
Owned After
6,600
SEC Form 4
Chang David J.
Buy
Chief Medical Officer
CABA Jan 21, 2026
Avg Cost/Share
$2.26
Shares
8,800
Total Value
$19,888.00
Owned After
8,800
SEC Form 4
Nichtberger Steven
Buy
President & CEO
CABA Jan 21, 2026
Avg Cost/Share
$2.24
Shares
45,000
Total Value
$100,777.50
Owned After
1,031,483
SEC Form 4
Tomasello Shawn
Buy
Director
CABA Jan 21, 2026
Avg Cost/Share
$2.21
Shares
22,725
Total Value
$50,322.24
Owned After
22,725
SEC Form 4
Bollard Catherine
Buy
Director
CABA Jan 21, 2026
Avg Cost/Share
$2.27
Shares
4,405
Total Value
$9,982.17
Owned After
5,405
SEC Form 4
Simon Mark
Buy
Director
CABA Jan 21, 2026
Avg Cost/Share
$2.28
Shares
11,061
Total Value
$25,261.11
Owned After
147,205
SEC Form 4
Gavel Steve
Buy
Chief Commercial Officer
CABA Jan 21, 2026
Avg Cost/Share
$2.27
Shares
22,170
Total Value
$50,215.05
Owned After
22,170
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | CABA | President, Science & Tech. | Jan 21, 2026 | Buy | $2.19 | 11,312 | $24,763.10 | 31,312 | |
| Gerard Michael | CABA | General Counsel | Jan 21, 2026 | Buy | $2.27 | 6,600 | $14,979.36 | 6,600 | |
| Chang David J. | CABA | Chief Medical Officer | Jan 21, 2026 | Buy | $2.26 | 8,800 | $19,888.00 | 8,800 | |
| Nichtberger Steven | CABA | President & CEO | Jan 21, 2026 | Buy | $2.24 | 45,000 | $100,777.50 | 1,031,483 | |
| Tomasello Shawn | CABA | Director | Jan 21, 2026 | Buy | $2.21 | 22,725 | $50,322.24 | 22,725 | |
| Bollard Catherine | CABA | Director | Jan 21, 2026 | Buy | $2.27 | 4,405 | $9,982.17 | 5,405 | |
| Simon Mark | CABA | Director | Jan 21, 2026 | Buy | $2.28 | 11,061 | $25,261.11 | 147,205 | |
| Gavel Steve | CABA | Chief Commercial Officer | Jan 21, 2026 | Buy | $2.27 | 22,170 | $50,215.05 | 22,170 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 10, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 10, 2025 · 100% conf.
AI Prediction SELL
1D
-4.07%
$2.33
Act: +1.65%
5D
-12.77%
$2.12
Act: -1.65%
20D
-8.89%
$2.21
Act: +2.88%
Price: $2.43 Prob +5D: 0% AUC: 1.000
0001193125-25-273272
8-K
0001759138false00017591382025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10, 2025
CABALETTA BIO, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-39103
82-1685768
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2929 Arch Street Suite 600
Philadelphia, Pennsylvania
19104
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (267) 759-3100
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00001 per share
CABA
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 10, 2025, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
99.1
Press Release issued by the registrant on November 10, 2025, furnished herewith.
104
Cover Page Interactive Data File (embedded within the Inline XBRL Document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CABALETTA BIO, INC.
Date: November 10, 2025
By:
/s/ Steven Nichtberger
Steven Nichtberger
Chief Executive Officer and President (Principal Executive Officer)
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0000950170-25-104570
8-K
false000175913800017591382025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 07, 2025
CABALETTA BIO, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-39103
82-1685768
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2929 Arch Street Suite 600
Philadelphia, Pennsylvania
19104
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (267) 759-3100
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00001 per share
CABA
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) announced its financial results for the second quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
99.1
Press Release issued by the registrant on August 7, 2025, furnished herewith.
104
Cover Page Interactive Data File (embedded within the Inline XBRL Document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CABALETTA BIO, INC.
Date: August 7, 2025
By:
/s/ Steven Nichtberger
Steven Nichtberger
Chief Executive Officer and President (Principal Executive Officer)
2025 Q1 Q1 2025 Earnings
8-K May 15, 2025
2025
Q1
Q1 2025 Earnings
8-KMay 15, 2025
0000950170-25-071966
8-K
0001759138false00017591382025-05-152025-05-15
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2025
CABALETTA BIO, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-39103
82-1685768
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2929 Arch Street Suite 600
Philadelphia, Pennsylvania
19104
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (267) 759-3100
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00001 per share
CABA
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On May 15, 2025, Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) disclosed that its cash and cash equivalents as of March 31, 2025 was $131.8 million, compared to $164.0 million as of December 31, 2024. The Company expects that this cash position as of March 31, 2025 will enable it to fund its operating plan into the first half of 2026. The information contained in Item 2.02 of this Form 8-K does not present all information necessary for an understanding of the Company’s financial condition as of March 31, 2025 and is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 7.01 Regulation FD Disclosure On May 15, 2025, the Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation (the “Corporate Presentation”). On May 15, 2025, the Company issued a Press Release entitled “Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts” (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
99.1
Press Release issued by the registrant on May 15, 2025, furnished herewith.
104
Cover Page Interactive Data File (embedded within the Inline XBRL Document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CABALETTA BIO, INC.
Date: May 15, 2025
By:
/s/ Steven Nichtberger
Steven Nichtberger
Chief Executive Officer and President (Principal Executive Officer)
Latest Cabaletta Bio Inc. News
CABA Breaking Stock News: Dive into CABA Ticker-Specific Updates for Smart Investing
Argus Research
Daily – Vickers Top Insider Picks for 03/16/2026
Argus Research
Daily – Vickers Top Insider Picks for 03/13/2026
Argus Research
Daily – Vickers Top Insider Picks for 03/12/2026
Compare CABA vs Leading Stocks
See how CABA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CABA Cabaletta Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.